ARTICLE | Strategy

By (some of) the numbers

How ICER concluded new HCV drugs Sovaldi, Olysio not worth their costs

March 24, 2014 7:00 AM UTC

According to the Institute for Clinical and Economic Review and its California affiliate, the value of new HCV drugs Sovaldi sofosbuvir from Gilead Sciences Inc. and Olysio simeprevir from Johnson & Johnson is low because their benefits are not worth the costs.

The new drugs offer patients big improvements in cure rates, side effects and convenience compared with first-generation protease inhibitors that have become standard of care (see Cover Story). ...